Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04236635 · ClinicalTrials.gov registry record · Phase 2
Histopathology Following CCH Injection
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04236635: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT04236635 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04236635, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
To evaluate the histopathology of subcutaneous tissue isolated after single or multiple Collagenase Clostridium Histolyticum (CCH) injection techniques in adult female participants undergoing abdominoplasty.
Interventions
- DRUG Collagenase Clostridium Histolyticum Single Injection Technique
- DRUG Collagenase Clostridium Histolyticum Multiple Injection Technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-12-20 |
| Est. Completion | 2020-10-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04236635
The ClinicalTrials.gov registry entry for NCT04236635 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Collagenase Clostridium Histolyticum Single Injection Technique is the first listed.
NCT04236635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04236635 about?
NCT04236635 is a clinical study titled "Histopathology Following CCH Injection". To evaluate the histopathology of subcutaneous tissue isolated after single or multiple Collagenase Clostridium Histolyticum (CCH) injection techniques in adult female participants undergoing abdominoplasty.
What is the current status of trial NCT04236635?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-12-20. Estimated completion is 2020-10-26.
What interventions are being tested in trial NCT04236635?
The interventions under investigation include: Collagenase Clostridium Histolyticum Single Injection Technique (DRUG), Collagenase Clostridium Histolyticum Multiple Injection Technique (DRUG).
Who is sponsoring clinical trial NCT04236635?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.